Chaitra Ujjani
Overview
Explore the profile of Chaitra Ujjani including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
45
Citations
301
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chavez J, Dickinson M, Munoz J, Ulrickson M, Thieblemont C, Oluwole O, et al.
Blood
. 2025 Feb;
PMID: 39938019
ZUMA-12 is a multicenter phase 2 study that evaluated axicabtagene ciloleucel (axi-cel), an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, as part of first-line treatment in patients with high-risk...
2.
Samples L, Sadrzadeh H, Frigault M, Jacobson C, Hamadani M, Gurumurthi A, et al.
Blood
. 2025 Feb;
PMID: 39938007
Burkitt lymphoma (BL) is an aggressive B-cell lymphoma associated with poor outcomes in patients with relapsed/refractory disease. This multicenter, retrospective study evaluated real-world CD19 CAR T-cell therapy outcomes in patients...
3.
Ghosh N, Eyre T, Brown J, Lamanna N, Manzoor B, Coombs C, et al.
Am J Hematol
. 2024 Dec;
100(3):511-515.
PMID: 39698781
No abstract available.
4.
Woolston D, Lee N, Shadman M, Latorre-Esteves E, Tee X, Fredrickson J, et al.
Haematologica
. 2024 Jul;
109(7):2378.
PMID: 38946649
No abstract available.
5.
Wierda W, Brown J, Abramson J, Awan F, Bilgrami S, Bociek G, et al.
J Natl Compr Canc Netw
. 2024 Apr;
22(3):175-204.
PMID: 38626800
Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are essentially different manifestations of the same disease that are similarly managed. A number of molecular and cytogenetic variables with prognostic...
6.
Samples L, Voutsinas J, Fakhri B, Khajavian S, Spurgeon S, Stephens D, et al.
Blood Adv
. 2024 Feb;
8(9):2085-2093.
PMID: 38315043
Although Bruton tyrosine kinase inhibitors (BTKis) are generally well tolerated and less toxic than chemotherapy alternatives used to treat lymphoid malignancies, BTKis like ibrutinib have the potential to cause new...
7.
Ujjani C
Hematology Am Soc Hematol Educ Program
. 2023 Dec;
2023(1):421-426.
PMID: 38066921
The treatment landscape of chronic lymphocytic leukemia (CLL) has evolved considerably over the past decade due to the development of effective novel agents with varying mechanisms of action, including Bruton...
8.
Woolston D, Lee N, Shadman M, Latorre-Esteves E, Tee X, Fredrickson J, et al.
Haematologica
. 2023 Sep;
109(3):835-845.
PMID: 37706363
BTK inhibitors, Bcl-2 inhibitors, and other targeted therapies have significantly improved the outcomes of patients with chronic lymphocytic leukemia (CLL). With increased survivorship, monitoring disease and deciphering potential mechanisms of...
9.
Shadman M, Manzoor B, Sail K, Tuncer H, Allan J, Ujjani C, et al.
Clin Lymphoma Myeloma Leuk
. 2023 Apr;
23(7):515-526.
PMID: 37076367
Introduction: This study assessed treatment discontinuation patterns and reasons among chronic lymphocytic leukemia (CLL) patients initiating first-line (1L) and second-line (2L) treatments in real-world settings. Materials And Methods: Using deidentified...
10.
Ujjani C, Gooley T, Spurgeon S, Stephens D, Lai C, Broome C, et al.
Blood Adv
. 2022 Dec;
7(17):4728-4737.
PMID: 36516082
Previous studies have demonstrated low rates of seroconversion to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) messenger RNA (mRNA) vaccines in patients with chronic lymphocytic leukemia (CLL). In this national...